Related Experiment Video
Updated: Jun 21, 2025
A Silver Nanoparticle Method for Ameliorating Biliary Atresia Syndrome in Mice
Published on: October 13, 2018
Clinical effect of spleen aminopeptide on improving liver function damage and immune function in children with infant
Xiao-Qing Fang1, Tian Gan2, Lie-Min Wang3
1Department of Pediatrics, General Hospital of Central Theater Command of PLA, Wuhan 430061, Hubei Province, China.
Insights
Arsphenamine-based peptides significantly improved liver function and immune status in infants with hepatitis syndrome (IHS). This treatment also reduced adverse effects compared to reduced glutathione alone.
Area of Science:
- Pediatrics
- Hepatology
- Immunology
Background:
- Infant hepatitis syndrome (IHS) presents with jaundice, abnormal liver function, and hepatomegaly in infants under one year.
- Various etiologies, including infections, can cause IHS.
Purpose of the Study:
- To evaluate the efficacy of arsphenamine-based peptides in treating IHS.
- To assess the impact on liver function damage and immune function in IHS patients.
Main Methods:
- A randomized controlled trial involving 100 IHS patients (50 per group) from January 2019 to January 2021.
- Treatment group received sesquiterpene peptide (arsphenamine-based) plus reduced glutathione.
- Control group received reduced glutathione alone.
Main Results:
- The treatment group showed significantly lower serum total bilirubin, direct bilirubin, and alanine transferase levels post-treatment (P < 0.05).
- Immune markers (CD4+, CD3+, CD4+/CD8+) were significantly higher in the treatment group (P < 0.05).
- Adverse events like rash, cough, elevated platelets, and gastrointestinal reactions were significantly reduced in the treatment group (P < 0.05).
Conclusions:
- Arsphenamine-based peptide combined with reduced glutathione is a more effective treatment for infant hepatitis syndrome.
- This combination therapy improves liver function and immune status while minimizing complications.
Background:
Infant hepatitis syndrome (IHS) is a clinical syndrome in infants less than one year of age with generalized skin jaundice, abnormal liver function, and hepatomegaly due to various etiologies such as infection.
Aim:
To investigate the effect of IHS patients, after treatment with arsphenamine-based peptides, on patients' liver function damage and immune function.
Methods:
Of 110 patients with IHS treated in our hospital from January 2019 to January 2021 were grouped according to the randomized residual grouping method, with 5 cases in each group shed due to transfer, etc. Ultimately, 50 cases remained in each group. The control group was treated with reduced glutathione, and the treatment group was treated with sesquiterpene peptide based on the control group. Observe and compare the differences in indicators after treatment.
Results:
The comparison of serum total bilirubin, direct bilirubin, and serum alanine transferase after treatment was significantly different and lower in the treatment group than in the control group (P < 0.05). The comparison of CD4+, CD3+, CD4+/CD8+ after treatment was significantly different and higher in the treatment group than in the control group, and the comparison was statistically significant (P < 0.05). The complication of the two groups showed that the rash, cough and sputum, elevated platelets, and gastrointestinal reactions in the treatment group were significantly lower than those in the control group, and the differences were statistically significant by test (P < 0.05).
Conclusion:
The comparative study of IHS treated with arsphenamine combined with reduced glutathione is more effective.
